From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Considerations and Collaboration

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Administration and Management

Interview with Danielle Roberts, PA-C: Sequencing of Bispecific Antibodies and CAR T-Cell Therapies

Interview with Danielle Roberts, PA-C: Onboarding APPs New to Multiple Myeloma Practice

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Evolving Technology and Monitoring of Disease

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Real-World Treatment and Transplant Strategies

The New Role of MRD Testing in Trials and Treatments

New Trial Data and the Ever-Changing Treatment Landscape

Interview with Sara Scott, PharmD, BCOP: Evolving Treatment Methods

Interview with Sara Scott, PharmD, BCOP: Role of the Clinical Pharmacist and the Multi-team Approach

Interview with Mary Steinbach, DNP, APRN: Clinical Trials and the Role of the AP

Interview with Mary Steinbach, DNP, APRN: Bispecifics vs CAR T-Cell Therapy in Multiple Myeloma Treatment

Interview with Amy Pierre, MSN, ANP-BC: Treatment and Care Inequities in Black Patients with Multiple Myeloma

Interview with Amy Pierre, MSN, ANP-BC: Choosing the Best Treatment Option for Your Patient

Relapsed Multiple Myeloma Treated with Teclistamab

Treatment of Intermediate Risk Smoldering Myeloma

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy